How Does Glucagon Nasal Spray Work?
The glucagon nasal spray (Baqsimi) delivers a 29-amino-acid peptide dry powder with the absorption enhancer dodecylphosphocholine for severe hypoglycemia. Phase III trials demonstrate 98.7% success and median recovery in 15 minutes, comparable to injectable GlucaGen. Unlike injectables needing cold chain and reconstitution, Baqsimi offers room-temperature stability (36 months) and a ready-to-use, needle-free device, reducing logistical burden. With a market exceeding $500 million and >15% CAGR, it fuels the intranasal peptide sector. FDA/EMA approved under cGMP, it sets standards for peptide product selection, emphasizing non-invasive routes and simplified shipping. The transmucosal absorption bypasses first-pass metabolism, guiding peptide selection toward patient-friendly, logistically simpler options.